Bonds v. Tandy

457 F.3d 409, 2006 U.S. App. LEXIS 18121, 2006 WL 1999162
CourtCourt of Appeals for the Fifth Circuit
DecidedJuly 19, 2006
Docket05-60478
StatusPublished
Cited by38 cases

This text of 457 F.3d 409 (Bonds v. Tandy) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bonds v. Tandy, 457 F.3d 409, 2006 U.S. App. LEXIS 18121, 2006 WL 1999162 (5th Cir. 2006).

Opinion

PRADO, Circuit Judge:

Michael Bonds petitions for review of the Drug Enforcement Administration’s (“DEA”) decision denying Rick Quinn’s waiver application that would have allowed Medical Plaza Pharmacy (“MPP”) to hire Bonds. Because we hold that 21 U.S.C. § 877 limits petitions for judicial review to those litigants with Article III standing and who are also arguably within the zone of interests of the Controlled Substances Act (“CSA”), 1 we find that Bonds lacks standing to challenge the agency’s final decision. Accordingly, we dismiss the petition for lack of jurisdiction.

I. BACKGROUND

Bonds, currently a licensed pharmacist in the State of Mississippi, applied for employment as a pharmacist at MPP. Because Bonds had a prior felony conviction for the illegal distribution of a controlled substance, and because he once owned a pharmacy that had its DEA registration revoked, 21 C.F.R. § 1301.76 prevented MPP from hiring Bonds unless the DEA waives the restriction. 2 On August 23, 2004, Quinn, on behalf of MPP, applied for a waiver, but the DEA denied the application based on Bonds’s criminal history and the criminal histories of MPP’s owner and two of its former employees.

II. DISCUSSION

A. Standard of Review

Bonds petitions this Court for review, claiming that the DEA’s decision was arbitrary and not supported by substantial evidence. The Government counters that Bonds lacks standing to appeal the DEA’s decision. We review questions of jurisdiction, and specifically standing, de novo. See, e.g., Pederson v. La. State Univ., 213 F.3d 858, 869 (5th Cir.2000). Although the DEA raises standing, Bonds bears the burden of persuasion. BCCA Appeal Group v. U.S. Envtl. Prot. Agency, 355 F.3d 817, 825 (5th Cir.2003).

B. Scope of Judicial Review Under the Controlled Substances Act

The CSA’s judicial review provision provides that “any person aggrieved by a final decision of the Attorney General” may obtain review of “[a]ll final determinations, findings, and conclusions of the Attorney General under this subchapter.” 21 U.S.C. § 877. The Government contends that the CSA’s judicial review provision requires, at a minimum, two standing components, one constitutional, which is based on Article Ill’s provision for judicial review of a case or controversy, 3 and the other prudential. 4 Specifically, the Government argues that Bonds lacks standing because he fails to meet the prudential *412 standing requirements. It contends that Bonds is not a “person aggrieved” under the CSA because: (1) the alleged injury-does not fall within the zone of interests protected or regulated by the CSA; (2) Bonds is not an employer-registrant or waiver applicant; and (3) Bonds cannot raise the legal rights of a third party. Bonds asserts that he meets the prudential standing requirements because he is a “person aggrieved” under the CSA’s judicial review provision, 21 U.S.C. § 877.

“The phrase ‘person adversely affected or aggrieved’ is a term of art used in many statutes to designate those who have standing to challenge or appeal an agency decision, within the agency or before the courts.” Dir., Office of Workers’ Comp. Programs v. Newport News Shipbuilding & Dry Dock Co., 514 U.S. 122, 126, 115 S.Ct. 1278, 131 L.Ed.2d 160 (1995). We have not yet addressed the scope of the term “person aggrieved” under 21 U.S.C. § 877. Because Congress could have, through 21 U.S.C. § 877, expanded judicial reviewability to litigants who do not meet the prudential standing requirements, we look to the Act to determine whether Congress intended the prudential standing doctrine to apply to suits brought under the CSA. See Assoc. of Cmty. Orgs. for Reform Now v. Fowler, 178 F.3d 350, 356, 363 (5th Cir.1999). However, we recognize that “Congress legislates against the background of [the] prudential standing doctrine, which applies unless it is expressly negated.” Bennett v. Spear, 520 U.S. 154, 163, 117 S.Ct. 1154, 137 L.Ed.2d 281 (1997).

In drafting the CSA, Congress did not expressly expand judicial review to litigants not meeting the prudential standing requirements. 5 Moreover, in the context of the similarly-worded judicial review provision in the Administrative Procedure Act (“APA”), the Supreme Court, in Newport News, suggested that to be a person aggrieved, the litigant must “show at the outset of the case, that he is injured in fact by agency action and that the interest he seeks to vindicate is arguably within the ‘zone of interests to be protected or regulated by the statute’ in question.” 6 Id. at 126-27, 115 S.Ct. 1278 (citation omitted).

*413 The D.C. Circuit applied Newport News, and also reached our conclusion regarding the standing requirements under 21 U.S.C. § 877. In PDK Laboratories Inc. v. United States Drug Enforcement Administration, the court stated:

In view of the interpretation of statutes applicable to other agencies containing language identical to § 877, we hold that if PDK has Article III standing, which no one doubts, and if its interests are “arguably within the zone of interests” § 971(c)(1) regulates, which we believe they are, PDK is a “person aggrieved” within § 877’s meaning and is entitled to prosecute its case in court.

362 F.3d 786, 793 (D.C.Cir.2004)(citing Newport News, 514 U.S. at 126-27, 115 S.Ct. 1278). Therefore, according to PDK Laboratories, the term “person aggrieved” merely requires that the litigant have Article III standing and prudential standing- — i.e., arguably be within the “zone of interests.” We agree with the D.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Jarrod Stringer v. David Whitley
942 F.3d 715 (Fifth Circuit, 2019)
In Re: Deepwater Horizon
739 F.3d 790 (Fifth Circuit, 2014)
L & F Homes & Development, L.L.C. v. City of Gulfport
538 F. App'x 395 (Fifth Circuit, 2013)
United States v. $119,030.00 in U.S. Currency
955 F. Supp. 2d 569 (W.D. Virginia, 2013)
Walters v. UPMC Presbyterian Shadyside
31 Pa. D. & C.5th 281 (Alleghany County Court of Common Pleas, 2013)
United States v. 2004 Ferrari 360 Modeno
902 F. Supp. 2d 944 (S.D. Texas, 2012)
MC Asset Recovery LLC v. Commerzbank A.G.
675 F.3d 530 (Fifth Circuit, 2012)
Spicer v. Laguna Madre Oil & Gas II, L.L.C.
647 F.3d 547 (Fifth Circuit, 2011)
Villas at Parkside Partners v. City of Farmers Branch
701 F. Supp. 2d 835 (N.D. Texas, 2010)
Adar v. Smith
597 F.3d 697 (Fifth Circuit, 2010)
United States v. $500,000.00 in U.S. Currency
591 F.3d 402 (Fifth Circuit, 2009)
Cimerring v. Orix Capital Markets, LLC
323 F. App'x 306 (Fifth Circuit, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
457 F.3d 409, 2006 U.S. App. LEXIS 18121, 2006 WL 1999162, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bonds-v-tandy-ca5-2006.